TwoStep
TwoStep Therapeutics is redefining targeted cancer therapy with PIP, an engineered peptide that binds integrin receptors on solid tumors.
Challenge
How do you launch Nobel-backed science as a category of its own, then carry that same story through a Series A and into the clinic two years later?
Approach
TwoStep partnered with Thermal for its company launch, Series A, and FDA clearance for its lead drug.
- Defined positioning and messaging at launch: Framed PIP’s multi-target mechanism as a way past the single-antigen limits holding solid tumor therapies back, working directly with the founding team, including Nobel laureate Carolyn Bertozzi.
- Built the brand and social foundation: Stood up TwoStep’s early brand voice and social presence to carry the launch story past the initial press cycle.
- Executed an embargoed exclusive launch strategy: Pitched Kyle LaHucik at Endpoints News on an exclusive introducing TwoStep as it emerged from Stanford’s Innovative Medicines Accelerator.
- Prepared leadership for a high-stakes financing interview: Media trained CEO Caitlyn Miller ahead of a second Endpoints exclusive, this time on the Series A and IND clearance.
- Rebuilt the digital presence for a clinical-stage company: Partnered with a design agency to redesign TwoStep’s website to reflect their evolution into a clinical-stage company.
“With its ability to carry diverse payloads and versatility to any kind of solid tumor, TwoStep’s tumor-targeting technology has the makings of a powerful and attractive tool for a wide array of tumors that have been historically difficult to treat.”
Carolyn Bertozzi – Nobel Laureate & co-founder of TwoStep Therapeutics
Impact
Together, we:
- Launched with a feature in Endpoints News: Secured TwoStep’s debut trade coverage, introducing the company and its multi-targeting approach to the biotech industry.
- Earned follow-on coverage in GEN: A second launch feature extended reach beyond the initial exclusive.
- Secured a second Endpoints exclusive for the Series A/IND news: Thermal’s strategic approach to messaging and exclusive embargo outreach earned a feature story in Endpoints News, plus coverage in other key business and trade publications.
“Our initial focus at TwoStep is to couple our tumor-targeting technology with clinically-validated payloads, which has the potential to extend the benefits of paradigm-shifting therapies to a greater number of patients.”
Caitlyn Miller – Co-founder and CEO of TwoStep Therapeutics
